亚盛医药(AAPG)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AAPG 亚盛医药

已收盘 05-06 16:00:00 EDT

25.80

+0.50

+1.98%

盘后25.80

+0.000.00%

18:17 EDT

最高26.00	最低24.63	成交量3.75万
今开25.50	昨收25.30	日振幅5.41%
总市值22.09亿	流通市值2.13亿	总股本8,564万
成交额96.42万	换手率0.45%	流通股本826.01万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AAPG","market":"US","secType":"STK","nameCN":"亚盛医药","latestPrice":25.8,"timestamp":1746561600000,"preClose":25.3,"halted":0,"volume":37538,"hourTrading":{"tag":"盘后","latestPrice":25.8,"preClose":25.8,"latestTime":"18:17 EDT","volume":20,"amount":513,"timestamp":1746569864685},"delay":0,"floatShares":8260100,"shares":85636946,"eps":-0.735552,"marketStatus":"已收盘","change":0.5,"latestTime":"05-06 16:00:00 EDT","open":25.5,"high":26,"low":24.6301,"amount":964242.2847239999,"amplitude":0.054146,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.735552,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1746604800000},"marketStatusCode":5,"adr":0,"adrRate":4,"listingDate":1737694800000,"exchange":"NASDAQ","adjPreClose":25.3,"preHourTrading":{"tag":"盘前","latestPrice":25.31,"preClose":25.3,"latestTime":"09:08 EDT","volume":10,"amount":253.1,"timestamp":1746536889550},"postHourTrading":{"tag":"盘后","latestPrice":25.8,"preClose":25.8,"latestTime":"18:17 EDT","volume":20,"amount":513,"timestamp":1746569864685},"volumeRatio":2.936235},"requestUrl":"/m/hq/s/AAPG","defaultTab":"news","newsList":[{"id":"2533911095","title":"亚盛医药5月5日成交额为33.42万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533911095","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533911095?lang=zh_cn&edition=full","pubTime":"2025-05-06 09:15","pubTimestamp":1746494110,"startTime":"0","endTime":"0","summary":"美东时间2025年5月5日，亚盛医药成交额为33.42万美元，成交额较昨日减少17.07%，当日成交量为1.32万股。亚盛医药于2025年5月5日跌0.71%，报25.3美元，该股过去5个交易日涨0.04%，年初至今涨46.67%，过去60日涨34.57%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-05-05|33.42万|-17.07%|1.32万|#|2025-05-02|40.30万|156.00%|1.59万|#|2025-05-01|15.74万|-69.34%|6332.00|#|2025-04-30|51.34万|176.53%|2.09万|#|2025-04-29|18.57万|26.02%|7560.00|亚盛医药集团是一家临床阶段的生物技术公司，从事癌症、乙型肝炎病毒和某些年龄相关疾病的创新小分子疗法的开发和销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506091516a4735099&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506091516a4735099&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2532654801","title":"亚盛医药5月2日成交额为40.30万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2532654801","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532654801?lang=zh_cn&edition=full","pubTime":"2025-05-03 09:15","pubTimestamp":1746234911,"startTime":"0","endTime":"0","summary":"美东时间2025年5月2日，亚盛医药成交额为40.30万美元，成交额较昨日增加156.00%，当日成交量为1.59万股。亚盛医药于2025年5月2日涨1.31%，报25.48美元，该股过去5个交易日跌3.12%，年初至今涨47.71%，过去60日涨41.16%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-05-02|40.30万|156.00%|1.59万|#|2025-05-01|15.74万|-69.34%|6332.00|#|2025-04-30|51.34万|176.53%|2.09万|#|2025-04-29|18.57万|26.02%|7560.00|#|2025-04-28|14.73万|-86.22%|5810.00|亚盛医药集团是一家临床阶段的生物技术公司，从事癌症、乙型肝炎病毒和某些年龄相关疾病的创新小分子疗法的开发和销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250503091519a4707e87&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250503091519a4707e87&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2532310017","title":"亚盛医药4月30日成交额为51.34万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2532310017","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532310017?lang=zh_cn&edition=full","pubTime":"2025-05-01 09:15","pubTimestamp":1746062111,"startTime":"0","endTime":"0","summary":"美东时间2025年4月30日，亚盛医药成交额为51.34万美元，成交额较昨日增加176.53%，当日成交量为2.09万股。亚盛医药于2025年4月30日涨0.95%，报24.43美元，该股过去5个交易日涨2.22%，年初至今涨41.62%，过去60日涨34.23%。该公司的地理部门包括美国和中国大陆。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501091517a6cf8335&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501091517a6cf8335&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2531213584","title":"亚盛医药4月28日成交额为14.73万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531213584","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531213584?lang=zh_cn&edition=full","pubTime":"2025-04-29 09:15","pubTimestamp":1745889311,"startTime":"0","endTime":"0","summary":"美东时间2025年4月28日，亚盛医药成交额为14.73万美元，成交额较昨日减少86.22%，当日成交量为5810.00股。亚盛医药于2025年4月28日跌3.82%，报25.29美元，该股过去5个交易日涨32.27%，年初至今涨46.61%，过去60日涨43.69%。该公司的地理部门包括美国和中国大陆。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429091517a6cc6c54&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429091517a6cc6c54&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2531268664","title":"【直击AACR 2025】亚盛医药公布五项临床前进展，耐立克®联合APG-2575展现显著协同效应","url":"https://stock-news.laohu8.com/highlight/detail?id=2531268664","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531268664?lang=zh_cn&edition=full","pubTime":"2025-04-28 23:13","pubTimestamp":1745853180,"startTime":"0","endTime":"0","summary":"特别值得关注的是，公司两个重磅品种奥雷巴替尼与APG-2575联合用药在AML及T-ALL模型中的协同效应，有望为相关治疗领域带来新的治疗方案。总结：   在维奈克拉耐药AML细胞系中，奥雷巴替尼联合APG-2575协同抑制了细胞增殖并诱导了细胞凋亡。新型Bcl-2抑制剂APG-2575目前正在针对多种血液恶性肿瘤的开展多项后期临床试验。该联合方案在MOLT4异种移植模型中同样表现出显著的协同抑瘤效应。APG-5918与恩扎卢胺联合用药表现出协同抑制细胞增殖的效应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4674082_ZH74082_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1574","LU2125909916.SGD","BK4139","BK1161","BK4129","APG","LU2125909759.SGD","06855","LU1923622291.USD","AAPG"],"gpt_icon":0},{"id":"2530387403","title":"亚盛医药-B(06855)五项临床前进展亮相2025年AACR年会，耐立克®联合APG-2575展现显著协同效应","url":"https://stock-news.laohu8.com/highlight/detail?id=2530387403","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530387403?lang=zh_cn&edition=full","pubTime":"2025-04-28 19:49","pubTimestamp":1745840941,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，公司于2025年4月25日至2025年4月30日在美国芝加哥举行的2025年美国癌症研究协会年会上，以壁报形式公布了五项临床前研究成果。本次壁报涉及公司五个品种，包括：原创1类新药奥雷巴替尼、Bcl-2抑制剂APG-2575、FAK/ALK/ROS1三联酪氨酸激酶抑制剂APG-2449、胚胎外胚层发育蛋白抑制剂APG-5918以及IAP拮抗剂AS03157。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1286639.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1923622291.USD","AAPG","BK4129","LU2125909916.SGD","BK1574","LU2125909759.SGD","APG","06855","BK1161","BK4139"],"gpt_icon":0},{"id":"2530914089","title":"亚盛医药4月24日成交额为163.21万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530914089","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530914089?lang=zh_cn&edition=full","pubTime":"2025-04-25 09:15","pubTimestamp":1745543709,"startTime":"0","endTime":"0","summary":"美东时间2025年4月24日，亚盛医药成交额为163.21万美元，成交额较昨日增加28.83%，当日成交量为6.38万股。亚盛医药于2025年4月24日涨6.69%，报25.5美元，该股过去5个交易日涨35.14%，年初至今涨47.83%，过去60日涨48.26%。它专注于开发抑制蛋白质间相互作用以恢复细胞凋亡或程序性细胞死亡的疗法。该公司的地理部门包括美国和中国大陆。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425091522a6c754c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425091522a6c754c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2529623787","title":"亚盛医药两项研究入选2025年ASCO年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2529623787","media":"财中社","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529623787?lang=zh_cn&edition=full","pubTime":"2025-04-24 15:06","pubTimestamp":1745478416,"startTime":"0","endTime":"0","summary":"4月24日，亚盛医药-B（06855）发布公告，宣布其两项研究成果入选2025年美国临床肿瘤学会（ASCO）年会。细胞凋亡管线重点品种Bcl-2选择性抑制剂Lisaftoclax（APG-2575）联合治疗髓系恶性肿瘤患者的Ib/II期研究最新进展将以口头报告的形式展示。该研究的摘要编号为6505，报告时间定于2025年6月2日下午15:00至18:00（美国中部时间）。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504243387193830.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2529269844","title":"亚盛医药-B(06855)两项研究入选2025年美国临床肿瘤学会年会 包括一个Lisaftoclax (APG-2575)口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2529269844","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529269844?lang=zh_cn&edition=full","pubTime":"2025-04-24 07:13","pubTimestamp":1745450023,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，公司细胞凋亡管线重点品种Bcl-2选择性抑制剂Lisaftoclax和MDM2-p53抑制剂Alrizomadlin 的两项临床研究成果入选2025年美国临床肿瘤学会年会，其中，APG-2575联合治疗髓系恶性肿瘤患者的Ib/II期研究最新进展获口头报告。本届ASCO年会将于2025年5月30日至2025年6月3日在芝加哥McCormick会议中心以线上线下结合的形式举办。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1283681.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["APG","06855","BK4129","BK1161","LU2125909759.SGD","BK1574","AAPG","LU1923622291.USD","LU2125909916.SGD","BK4139"],"gpt_icon":0},{"id":"2529759479","title":"亚盛医药4月22日成交额为258.18万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2529759479","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529759479?lang=zh_cn&edition=full","pubTime":"2025-04-23 09:15","pubTimestamp":1745370910,"startTime":"0","endTime":"0","summary":"美东时间2025年4月22日，亚盛医药成交额为258.18万美元，成交额较昨日增加1131.94%，当日成交量为12.01万股。亚盛医药于2025年4月22日涨12.97%，报21.6美元，该股过去5个交易日涨5.42%，年初至今涨25.22%，过去60日涨24.28%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-04-22|258.18万|1131.94%|12.01万|#|2025-04-21|20.96万|257.69%|1.10万|#|2025-04-17|5.86万|397.59%|3120.00|#|2025-04-16|1.18万|-99.34%|624.00|#|2025-04-15|178.96万|430.92%|9.15万|亚盛医药集团是一家临床阶段的生物技术公司，从事癌症、乙型肝炎病毒和某些年龄相关疾病的创新小分子疗法的开发和销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423091517a6c47820&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423091517a6c47820&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2529877876","title":"2025 CSCO指南更新：亚盛医药-B(06855)APG-2575首获推荐 耐立克®获升级推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2529877876","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529877876?lang=zh_cn&edition=full","pubTime":"2025-04-21 19:26","pubTimestamp":1745234776,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，公司自主研发的两款重磅创新药均获纳入2025年中国临床肿瘤学会系列指南：在研品种新型口服 Bcl-2选择性抑制剂Lisaftoclax首次获《CSCO淋巴瘤诊疗指南》推荐。2024年11月，Lisaftoclax单药治疗R/R CLL/SLL的NDA申请已获国家药监局药品审评中心受理并纳入优先审评。此次2025版《 CSCO儿童及青少年白血病诊疗指南》在针对费城染色体阳性急性淋巴细胞白血病儿童患者的治疗中，首次将奥雷巴替尼升级为I级推荐治疗方案用于BCR-ABL1激酶区T315I突变患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1281643.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1430594728.SGD","LU2237443382.USD","BK4527","IE00BVYPNV92.GBP","LU1066051225.USD","IE00BGHQF631.EUR","LU0348723411.USD","LU1880398471.USD","LU2237443549.SGD","LU1059921491.USD","LU2237443978.SGD","LU0731783394.SGD","IE00BVYPNW00.USD","LU0792757196.USD","IE00B3T34201.USD","BK4534","BK1574","LU1506573853.SGD","SG9999001440.SGD","LU2125909916.SGD","LU1599440770.SGD","LU0234572021.USD","LU1244550577.SGD","LU1571399168.USD","LU1880398554.USD","BK4533","06855","LU1585245621.USD","LU2237443622.USD","BK4525","IE00BSNM7G36.USD","BK4020","LU0823417737.USD","IE00BFXG1179.USD","APG","BK4560","BK4550","CSCO","LU1046421795.USD","LU2237443895.HKD","SG9999015952.SGD","BK4581","BK4579","LU0203345920.USD","AAPG","SG9999015945.SGD","SG9999015986.USD","LU1235294995.USD","LU0234570918.USD","LU0889566641.SGD"],"gpt_icon":0},{"id":"2528660701","title":"亚盛医药4月17日成交额为5.86万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2528660701","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528660701?lang=zh_cn&edition=full","pubTime":"2025-04-18 09:15","pubTimestamp":1744938909,"startTime":"0","endTime":"0","summary":"美东时间2025年4月17日，亚盛医药成交额为5.86万美元，成交额较昨日增加397.59%，当日成交量为3120.00股。亚盛医药于2025年4月17日跌0.79%，报18.72美元，该股过去5个交易日涨5.76%，年初至今涨8.52%，过去60日涨8.52%。该公司的地理部门包括美国和中国大陆。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250418091514a45d3b1e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250418091514a45d3b1e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2527096094","title":"亚盛医药4月15日成交额为178.96万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527096094","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527096094?lang=zh_cn&edition=full","pubTime":"2025-04-16 09:15","pubTimestamp":1744766109,"startTime":"0","endTime":"0","summary":"美东时间2025年4月15日，亚盛医药成交额为178.96万美元，成交额较昨日增加430.92%，当日成交量为9.15万股。亚盛医药于2025年4月15日跌5.08%，报19.45美元，该股过去5个交易日跌0.05%，年初至今涨12.75%，过去60日涨12.75%。它专注于开发抑制蛋白质间相互作用以恢复细胞凋亡或程序性细胞死亡的疗法。该公司的地理部门包括美国和中国大陆。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416091514a6bbdfde&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416091514a6bbdfde&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2527146766","title":"亚盛医药上涨11.66%，报20.88美元/股，总市值18.18亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527146766","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527146766?lang=zh_cn&edition=full","pubTime":"2025-04-15 03:58","pubTimestamp":1744660697,"startTime":"0","endTime":"0","summary":"4月15日，亚盛医药盘中上涨11.66%，截至03:58，报20.88美元/股，成交29.43万美元，总市值18.18亿美元。财务数据显示，截至2024年12月31日，亚盛医药收入总额9.81亿人民币，同比增长341.77%；归母净利润-4.05亿人民币，同比增长56.2%。目前公司正在中国、美国、澳大利亚及欧洲开展40多项临床试验。截至目前,公司共有4个在研新药获得16项FDA和1项欧盟孤儿药资格认定,2项FDA快速通道资格以及2项FDA儿童罕见病资格认证。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/15035849536897.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2526690131","title":"亚盛医药上涨7.29%，报18.991美元/股，总市值16.54亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2526690131","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2526690131?lang=zh_cn&edition=full","pubTime":"2025-04-12 00:05","pubTimestamp":1744387546,"startTime":"0","endTime":"0","summary":"4月12日，亚盛医药盘中上涨7.29%，截至00:05，报18.991美元/股，成交83.24万美元，总市值16.54亿美元。财务数据显示，截至2024年12月31日，亚盛医药收入总额9.81亿人民币，同比增长341.77%；归母净利润-4.05亿人民币，同比增长56.2%。目前公司正在中国、美国、澳大利亚及欧洲开展40多项临床试验。截至目前,公司共有4个在研新药获得16项FDA和1项欧盟孤儿药资格认定,2项FDA快速通道资格以及2项FDA儿童罕见病资格认证。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/12000549505844.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2517147943","title":"亚盛医药-B早盘涨超5% 耐立克®第三次获CDE纳入突破性治疗品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2517147943","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517147943?lang=zh_cn&edition=full","pubTime":"2025-03-07 10:47","pubTimestamp":1741315620,"startTime":"0","endTime":"0","summary":"　　亚盛医药-B早盘上涨5.07%，现报40.45港元，成交额7852.04万港元。　　亚盛医药-B发布公告，公司原创1类新药奥雷巴替尼获国家药品监督管理局药品审评中心纳入“突破性治疗品种”名单，用于联合化疗一线治疗新诊断费城染色体阳性（Ph+）急性淋巴细胞白血病患者。　　据悉，这是耐立克第三次获CDE纳入突破性治疗品种。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-03-07/doc-inenuuym7106212.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","CDE","BK4017","BK1161","AAPG","06855","BK1574"],"gpt_icon":0},{"id":"2517903144","title":"港股异动 | 亚盛医药-B(06855)盘中涨超4% 耐立克®第三次获CDE纳入突破性治疗品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2517903144","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517903144?lang=zh_cn&edition=full","pubTime":"2025-03-07 10:21","pubTimestamp":1741314098,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，亚盛医药-B盘中涨超4%，截至发稿，涨4.55%，报40.25港元，成交额5269.94万港元。消息面上，亚盛医药-B发布公告，公司原创1类新药奥雷巴替尼获国家药品监督管理局药品审评中心纳入“突破性治疗品种”名单，用于联合化疗一线治疗新诊断费城染色体阳性(Ph+)急性淋巴细胞白血病患者。据悉，这是耐立克第三次获CDE纳入突破性治疗品种。耐立克是亚盛医药原创1类新药，为中国首个获批上市的第三代BCR-ABL抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258906.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","CDE","BK4017","BK4139","BK1161","06855","BK1574"],"gpt_icon":0},{"id":"2517919705","title":"亚盛医药下跌2.26%，报19.03美元/股，总市值16.57亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517919705","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517919705?lang=zh_cn&edition=full","pubTime":"2025-03-07 04:18","pubTimestamp":1741292291,"startTime":"0","endTime":"0","summary":"3月7日，亚盛医药盘中下跌2.26%，截至04:18，报19.03美元/股，成交30.32万美元，总市值16.57亿美元。财务数据显示，截至2024年06月30日，亚盛医药收入总额8.24亿人民币，同比增长477.25%；归母净利润1.63亿人民币，同比增长140.51%。目前公司正在中国、美国、澳大利亚及欧洲开展40多项临床试验。截至目前,公司共有4个在研新药获得16项FDA和1项欧盟孤儿药资格认定,2项FDA快速通道资格以及2项FDA儿童罕见病资格认证。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/07041848578566.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2517975909","title":"亚盛医药耐立克再获“突破性治疗品种”认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2517975909","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517975909?lang=zh_cn&edition=full","pubTime":"2025-03-06 11:19","pubTimestamp":1741231199,"startTime":"0","endTime":"0","summary":"3月6日，亚盛医药-B（06855）发布公告，公司原创1类新药耐立克?（奥雷巴替尼）获得国家药品监督管理局药品审评中心纳入“突破性治疗品种”名单，用于联合化疗一线治疗新诊断的费城染色体阳性(Ph+)急性淋巴细胞白血病(ALL)患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503063338318229.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2517908543","title":"耐立克®治疗费城染色体阳性（Ph+）急性淋巴细胞白血病（ALL）获突破性疗法认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2517908543","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517908543?lang=zh_cn&edition=full","pubTime":"2025-03-06 09:42","pubTimestamp":1741225320,"startTime":"0","endTime":"0","summary":"美国马里兰州罗克维尔市和中国苏州2025年3月6日 /美通社/ -- 致力于在血液肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药今日宣布，公司原创1类新药奥雷巴替尼获国家药品监督管理局药品审评中心纳入\"突破性治疗品种\"名单，用于联合化疗一线治疗新诊断费城染色体阳性（Ph+）急性淋巴细胞白血病患者。此次耐立克获纳入突破性治疗品种，显示了该药物在Ph+ ALL这一预后恶劣的血液肿瘤治疗领域具重大临床潜力和价值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4634781_ZH34781_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2355687059.USD","BK4139","ALL","BK4588","LU0985320562.USD","06855","AAPG","BK4533","BK1574","LU1699723380.USD","LU1571399168.USD","BK1161","BK4585","BK4107"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascentage.com","stockEarnings":[{"period":"1week","weight":0.0004},{"period":"1month","weight":0.2076},{"period":"3month","weight":0.34},{"period":"6month","weight":0.4667},{"period":"ytd","weight":0.4667}],"compareEarnings":[{"period":"1week","weight":0.023},{"period":"1month","weight":0.1152},{"period":"3month","weight":-0.0636},{"period":"6month","weight":-0.0466},{"period":"1year","weight":0.1021},{"period":"ytd","weight":-0.0385}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"亚盛医药集团成立于2017年11月17日。亚盛医药集团是一家主要从事开发癌症、乙型肝炎病毒及若干衰老相关疾病的创新微型疗法的投资控股公司。该公司拥有自主研发的蛋白-蛋白相互作用靶向药物设计平台。该公司的主要产品包括下一代激酶抑制剂HQP1351,细胞凋亡靶向药物APG-1252、APG2575、APG-115等。该公司于国内市场及美国等海外市场开展业务。","exchange":"NASDAQ","name":"亚盛医药","nameEN":"ASCENTAGE PHARMA GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚盛医药(AAPG)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚盛医药(AAPG)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚盛医药,AAPG,亚盛医药股票,亚盛医药股票老虎,亚盛医药股票老虎国际,亚盛医药行情,亚盛医药股票行情,亚盛医药股价,亚盛医药股市,亚盛医药股票价格,亚盛医药股票交易,亚盛医药股票购买,亚盛医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚盛医药(AAPG)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚盛医药(AAPG)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}